We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.
BLPH

Delisted

BLPH was delisted on the 13th of October, 2023.

Back to rankings

37 hedge funds and large institutions have $47.3M invested in Bellerophon Therapeutics, Inc. in 2020 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 11 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

360% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 5

95% more funds holding

Funds holding: 19 → 37 (+18)

65% more capital invested

Capital invested by funds: $28.7M → $47.3M (+$18.6M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
37
Holders Change
+18
Holders Change %
+94.74%
% of All Funds
0.76%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
23
Increased
11
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NMVA
New Mountain Vantage Advisers
New York
+$12.7M
2
PCM
Puissance Capital Management
New York
+$8.4M
3
BlackRock
BlackRock
New York
+$3.99M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.93M
5
Renaissance Technologies
Renaissance Technologies
New York
+$2.08M

Top Sellers

Rank Fund Capital Flow
1
PI
Pennant Investors
New Jersey
-$769K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$261K
3
CH
CVI Holdings
Delaware
-$210K
4
Credit Agricole
Credit Agricole
France
-$35K
5
Victory Capital Management
Victory Capital Management
Texas
-$12K
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$20K +$22.2K +1,584 New
US Bancorp
27
US Bancorp
Minnesota
$15K – – –
UBS Group
28
UBS Group
Switzerland
$14K +$2.69K +192 +21%
CAN
29
Cetera Advisor Networks
California
$11K +$12.6K +900 New
SO
30
STRS Ohio
Ohio
$11K +$12.6K +900 New
Legal & General Group
31
Legal & General Group
United Kingdom
$7K +$7.93K +567 New
Citigroup
32
Citigroup
New York
$6K +$6.56K +469 New
Bank of Montreal
33
Bank of Montreal
Ontario, Canada
$4K +$3.85K +275 New
AIP
34
Ameritas Investment Partners
Nebraska
$4K +$4.25K +304 New
FANJ
35
Financial Architects (New Jersey)
New Jersey
$3K +$2.8K +200 New
TRCT
36
Tower Research Capital (TRC)
New York
$2K +$2.39K +171 New
FDCDDQ
37
Federation des caisses Desjardins du Quebec
Quebec, Canada
$841 – – –
PI
38
Pennant Investors
New Jersey
– -$769K -70,132 Closed
Hudson Bay Capital Management
39
Hudson Bay Capital Management
Connecticut
– -$261K -23,809 Closed
CH
40
CVI Holdings
Delaware
– -$210K -19,200 Closed
Credit Agricole
41
Credit Agricole
France
– -$35K -3,160 Closed
Victory Capital Management
42
Victory Capital Management
Texas
– -$12K -1,106 Closed
1
2

BLPH Hedge Fund Activity: Q2 2020 in Review

37 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q2 2020, worth a combined $47.3M — up 65% from $28.7M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new BLPH positions and 5 closed out — a net gain of 18 holders — while 11 added to existing stakes and 0 trimmed.

The largest buyer was New Mountain Vantage Advisers, adding an estimated $12.7M. The largest seller was Pennant Investors, exiting entirely with an estimated $769K sold.

  • 37 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q2 2020, up from 19 in Q1 2020.
  • Funds reported $47.3M of Bellerophon Therapeutics, Inc. stock for Q2 2020, up 65% quarter-over-quarter.
  • 23 funds opened new Bellerophon Therapeutics, Inc. positions in Q2 2020 and 5 closed out, a net change of +18 holders.
  • The largest Bellerophon Therapeutics, Inc. buyer in Q2 2020 was New Mountain Vantage Advisers, an estimated $12.7M added.
  • The largest Bellerophon Therapeutics, Inc. seller in Q2 2020 was Pennant Investors, an estimated $769K sold.

Based on aggregated 13F filings for Q2 2020.